替加环素（GAR-936）及其他12种抗菌药物对90株腐蚀艾肯菌临床分离株的体外活性
In vitro activities of tigecycline (GAR-936) and 12 other antimicrobial agents against 90 Eikenella corrodens clinical isolates.
作者信息
Cercenado Emilia, Cercenado Sonia, Bouza Emilio
机构信息
Servicio de Microbiología, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
出版信息
Antimicrob Agents Chemother. 2003 Aug;47(8):2644-5. doi: 10.1128/AAC.47.8.2644-2645.2003.
Abstract
The activity of tigecycline was compared with those of other antimicrobials against 90 isolates of Eikenella corrodens. The MIC at which 90% of the isolates were inhibited was 2 micro g/ml for tigecycline and 1, </=0.5/0.25, 0.5, </=0.12, </=2, and 0.5 micro g/ml for ampicillin, amoxicillin-clavulanate, cefotaxime, imipenem, chloramphenicol, and ciprofloxacin, respectively.
摘要
将替加环素与其他抗菌药物对90株腐蚀艾肯菌的活性进行了比较。替加环素对90%分离株产生抑制作用的最低抑菌浓度（MIC）为2μg/ml，氨苄西林、阿莫西林-克拉维酸、头孢噻肟、亚胺培南、氯霉素和环丙沙星的MIC分别为1、≤0.5/0.25、0.5、≤0.12、≤2和0.5μg/ml。
相似文献
1
In vitro activities of tigecycline (GAR-936) and 12 other antimicrobial agents against 90 Eikenella corrodens clinical isolates.
Antimicrob Agents Chemother. 2003 Aug;47(8):2644-5. doi: 10.1128/AAC.47.8.2644-2645.2003.
2
In vitro activities of a new des-fluoroquinolone, BMS 284756, and seven other antimicrobial agents against 151 isolates of Eikenella corrodens.
Antimicrob Agents Chemother. 2002 Apr;46(4):1141-3. doi: 10.1128/AAC.46.4.1141-1143.2002.
3
Clinical features of patients with invasive Eikenella corrodens infections and microbiological characteristics of the causative isolates.
Eur J Clin Microbiol Infect Dis. 2001 Apr;20(4):231-6. doi: 10.1007/pl00011259.
4
[Activity of 14 antimicrobials against Eikenella corrodens].
Rev Argent Microbiol. 2002 Oct-Dec;34(4):230-4.
5
In vitro activity of tigecycline against 3989 Gram-negative and Gram-positive clinical isolates from the United States Tigecycline Evaluation and Surveillance Trial (TEST Program; 2004).
Diagn Microbiol Infect Dis. 2005 Jul;52(3):173-9. doi: 10.1016/j.diagmicrobio.2005.06.004.
6
Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study.
Diagn Microbiol Infect Dis. 2006 Dec;56(4):437-44. doi: 10.1016/j.diagmicrobio.2006.07.005. Epub 2006 Sep 1.
7
Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936).
J Antimicrob Chemother. 2002 Mar;49(3):479-87. doi: 10.1093/jac/49.3.479.
8
Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
Int J Antimicrob Agents. 2009 Aug;34(2):121-30. doi: 10.1016/j.ijantimicag.2009.02.003. Epub 2009 Apr 1.
9
In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.
Int J Antimicrob Agents. 2014 Feb;43(2):170-8. doi: 10.1016/j.ijantimicag.2013.10.011. Epub 2013 Nov 15.
10
Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.
Antimicrob Agents Chemother. 2000 Oct;44(10):2747-51. doi: 10.1128/AAC.44.10.2747-2751.2000.
引用本文的文献
1
Antibiotics for treatment of resistant gram-positive coccal infections.
Indian J Pediatr. 2006 Apr;73(4):323-34. doi: 10.1007/BF02825827.
本文引用的文献
1
Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates.
Antimicrob Agents Chemother. 2003 Jan;47(1):400-4. doi: 10.1128/AAC.47.1.400-404.2003.
2
In vitro activities of a new des-fluoroquinolone, BMS 284756, and seven other antimicrobial agents against 151 isolates of Eikenella corrodens.
Antimicrob Agents Chemother. 2002 Apr;46(4):1141-3. doi: 10.1128/AAC.46.4.1141-1143.2002.
3
In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain.
Antimicrob Agents Chemother. 2002 Mar;46(3):892-5. doi: 10.1128/AAC.46.3.892-895.2002.
4
Susceptibilities of Eikenella corrodens, Prevotella intermedia, and Prevotella nigrescens clinical isolates to amoxicillin and tetracycline.
Antimicrob Agents Chemother. 2001 Nov;45(11):3253-5. doi: 10.1128/AAC.45.11.3253-3255.2001.
5
Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.
Antimicrob Agents Chemother. 2000 Oct;44(10):2747-51. doi: 10.1128/AAC.44.10.2747-2751.2000.
6
In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.
Antimicrob Agents Chemother. 2000 Aug;44(8):2225-9. doi: 10.1128/AAC.44.8.2225-2229.2000.
7
Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.
Diagn Microbiol Infect Dis. 2000 Jan;36(1):19-36. doi: 10.1016/s0732-8893(99)00092-9.
8
In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936).
Antimicrob Agents Chemother. 1999 Apr;43(4):738-44. doi: 10.1128/AAC.43.4.738.
9
Microbial etiological agents of destructive periodontal diseases.
Periodontol 2000. 1994 Jun;5:78-111. doi: 10.1111/j.1600-0757.1994.tb00020.x.
10
Comparison of broth microdilution method using Haemophilus test medium and agar dilution method for susceptibility testing of Eikenella corrodens.
J Clin Microbiol. 1998 Aug;36(8):2386-8. doi: 10.1128/JCM.36.8.2386-2388.1998.
Zotero 插件